Catabasis Pharmaceuticals and Duchenne UK Announce Partnership to Evaluate Edasalonexent in a Phase 2 Non-Ambulatory Duchenne Muscular Dystrophy Trial
— Duchenne UK Grants Over $600,000 in Funding to Support Patient and Clinical Trial Site Costs — BOSTON–(BUSINESS WIRE)–Catabasis Pharmaceuticals,…